Knockdown of TRIM47 inhibits breast cancer tumorigenesis and progression through the inactivation of PI3K/Akt pathway

被引:36
作者
Wang, Yaqiu [1 ]
Liu, Can [1 ]
Xie, Zhihui [1 ]
Lu, Hong [1 ]
机构
[1] Henan Univ, Dept Oncol, Huaihe Hosp, 8 Baobei Rd, Kaifeng 475000, Peoples R China
关键词
Tripartite totif 47 (TRIM47); Breast cancer; Tumorigenesis; PI3K/Akt signaling pathway; TUMOR-SUPPRESSOR; PROTEINS; AUTOPHAGY;
D O I
10.1016/j.cbi.2020.108960
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tripartite motif (TRIM) protein family is a group of proteins, which belongs to RING family of ubiquitin E3 ligases. TRIM proteins are involved in oncogenesis, while the roles in different cancers are controversial. However, the expression pattern and biological functions of TRIM47 in breast cancer remain unclear. In the present study, we aimed to investigate the function of TRIM47 in the progression and metastasis of breast cancer. TRIM47 was found to be significantly up-regulated in breast cancer tissues and cell lines. TRIM47 knockdown in breast cancer cell lines significantly inhibited cell proliferation, migration, and invasion. Besides, TRIM47 knockdown regulated the expressions of the epithelial-mesenchymal transition (EMT)-related markers including increase in E-cadherin, and decrease in N-cadherin, vimentin and Snail. Xenograft tumor assay proved that TRIM47 knockdown also suppressed tumor growth in vivo. Furthermore, TRIM47 knockdown markedly inhibited the activation of PI3K/Akt signaling pathway, while the effects of TRIM47 knockdown were reversed by the treatment of insulin-like growth factor-1 (IGF-1), which is an activator of PI3K/Akt. Taken together, the findings indicated that knockdown of TRIM47 suppressed tumorigenesis and progression of breast cancer through the inhibition of PI3K/Akt pathway, and suggested that TRIM47 might be a potential therapy target for breast cancer treatment.
引用
收藏
页数:8
相关论文
共 25 条
  • [1] TRIM29 Suppresses TWIST1 and Invasive Breast Cancer Behavior
    Ai, Lingbao
    Kim, Wan-Ju
    Alpay, Merve
    Tang, Ming
    Pardo, Carolina E.
    Hatakeyama, Shigetsugu
    May, W. Stratford
    Kladde, Michael P.
    Heldermon, Coy D.
    Siegel, Erin M.
    Brown, Kevin D.
    [J]. CANCER RESEARCH, 2014, 74 (17) : 4875 - 4887
  • [2] The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
    Bahrami, Afsane
    Khazaei, Majid
    Shahidsales, Soodabeh
    Hassanian, Seyed Mahdi
    Hasanzadeh, Malihe
    Maftouh, Mina
    Ferns, Gordon A.
    Avan, Amir
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (01) : 213 - 222
  • [3] Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab
    Basho, Reva K.
    Gilcrease, Michael
    Murthy, Rashmi K.
    Helgason, Thorunn
    Karp, Daniel D.
    Meric-Bernstam, Funda
    Hess, Kenneth R.
    Herbrich, Shelley M.
    Valero, Vicente
    Albarracin, Constance
    Litton, Jennifer K.
    Chavez-MacGregor, Mariana
    Ibrahim, Nuhad K.
    Murray, James L., III
    Koenig, Kimberly B.
    Hong, David
    Subbiah, Vivek
    Kurzrock, Razelle
    Janku, Filip
    Moulder, Stacy L.
    [J]. JAMA ONCOLOGY, 2017, 3 (04) : 509 - 515
  • [4] Type of Breast Cancer Diagnosis, Screening, and Survival
    Cedolini, Carla
    Bertozzi, Serena
    Londero, Ambrogio P.
    Bernardi, Sergio
    Seriau, Luca
    Concina, Serena
    Cattin, Federico
    Risaliti, Andrea
    [J]. CLINICAL BREAST CANCER, 2014, 14 (04) : 235 - 240
  • [5] Novel agents and associated toxicities of inhibitors of the PI3K/Akt/mTOR pathway for the treatment of breast cancer
    Chia, S.
    Gandhi, S.
    Joy, A. A.
    Edwards, S.
    Gorr, M.
    Hopkins, S.
    Kondejewski, J.
    Ayoub, J. P.
    Califaretti, N.
    Rayson, D.
    Dent, S. F.
    [J]. CURRENT ONCOLOGY, 2015, 22 (01) : 33 - 48
  • [6] Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
    Costa, Ricardo L. B.
    Han, Hyo Sook
    Gradishar, William J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (03) : 397 - 406
  • [7] The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia
    Dukel, Muzaffer
    Streitfeld, W. Scott
    Tang, Tsz Ching Chloe
    Backman, Lindsey R. F.
    Ai, Lingbao
    May, W. Stratford
    Brown, Kevin D.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (41) : 21541 - 21552
  • [8] The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
    Engelman, Jeffrey A.
    Luo, Ji
    Cantley, Lewis C.
    [J]. NATURE REVIEWS GENETICS, 2006, 7 (08) : 606 - 619
  • [9] Increased Expression of Tripartite Motif (TRIM) 47 Is a Negative Prognostic Predictor in Human Prostate Cancer
    Fujimura, Tetsuya
    Inoue, Satoshi
    Urano, Tomohiko
    Takayama, Kenich
    Yamada, Yuta
    Ikeda, Kazuhiro
    Obinata, Daisuke
    Ashikari, Daisaku
    Takahashi, Satoru
    Homma, Yukio
    [J]. CLINICAL GENITOURINARY CANCER, 2016, 14 (04) : 298 - 303
  • [10] Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
    Ghayad, Sandra E.
    Cohen, Pascale A.
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2010, 5 (01) : 29 - 57